SG Americas Securities LLC Lowers Position in DexCom, Inc. (NASDAQ:DXCM)

SG Americas Securities LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 91.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,824 shares of the medical device company's stock after selling 65,199 shares during the period. SG Americas Securities LLC's holdings in DexCom were worth $453,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. boosted its position in DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company's stock valued at $445,000 after purchasing an additional 162 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. Riverview Trust Co grew its stake in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after purchasing an additional 265 shares during the last quarter. Finally, Koa Wealth Management LLC increased its position in DexCom by 7.7% during the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company's stock worth $253,000 after buying an additional 270 shares during the period. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. StockNews.com downgraded shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Oppenheimer reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.41.

DexCom Trading Up 0.3 %

Shares of DXCM traded up $0.31 during trading hours on Wednesday, hitting $87.77. 185,027 shares of the stock were exchanged, compared to its average volume of 3,309,191. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a 50-day moving average of $80.95 and a 200-day moving average of $75.77. The firm has a market capitalization of $34.28 billion, a P/E ratio of 52.54, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.